Surprisingly, NMO patients show peculiar responses to treatment strategies involving type I interferons (I-IFN) like interferon-alpha (IFN-α) or interferon-beta (IFN-β), which sets them clearly apart from MS patients usually benefitting from such therapies [5–9]. This evidence concerns the gene IFNA1 and neuromyelitis optica.